Discover how the new p-tau217 blood test and the LEQEMBI IQLIK® autoinjector are revolutionizing Alzheimer's diagnosis and treatment at home.

Learn about the true economic and social impact of Alzheimer's, the burden on unpaid caregivers, and why diversity in medical research is key to a cure.

Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.

Discover how modern neurology is moving beyond amyloid to tackle atypical Alzheimer’s variants, neuroinflammation, and systemic factors for personalized care.

Discover why new Alzheimer's antibody treatments like lecanemab aren't enough on their own and why daily habits like exercise and diet play a critical role in brain health.

A study published in the American Journal of Epidemiology (August 2026) addressed this question. Researchers tracked cognitively healthy older adults over a 21-year period to evaluate how consistent, sustained fish consumption influences the long-term risk of developing Alzheimer's disease.

We often think of the heart and the brain as two separate systems—the pump and the computer. However, a groundbreaking study from Vanderbilt University Medical Center, recently highlighted in the journal Alzheimer's & Dementia, suggests that these two organs are more closely linked than we ever imagined.

For decades, the world of medical research has faced a quiet but massive problem: most clinical trials don't look like the real world. While science moves faster than ever, the way we find people to participate in life-saving studies is stuck in the past. This is especially true for underrepresented communities—including Black, Hispanic, and Asian Americans

When you or someone you love starts becoming a bit forgetful or feels like they are in a "fog," it is natural for your mind to jump to the scariest conclusion: Alzheimer's. That anxiety can be overwhelming, making every misplaced set of keys or forgotten name feel like a major warning sign.

Historically, scaling a clinical tool meant navigating a fragmented landscape where building a solution for one hospital required rewriting the code entirely for the next. This "bespoke barrier" has long been the primary bottleneck in scaling precision neurology.

If your clinical trial recruitment strategy still relies on cold-calling lists of "eligible" patients scraped from five-year-old EHR data, you aren’t just behind the times—you’re actively sabotaging your own FDA compliance.